Veraxa Biotech AG Announces Strategy to Adopt New Approach Methodologies Aligned with FDA
VRXA Veraxa Biotech AG
$1.08 -4.42%
View chart & analysis → - 1Veraxa Biotech AG announced a strategy to introduce New Approach Methodologies aligned with the FDA into its preclinical programs.
- 2Veraxa Biotech AG shares rose 3.7% in premarket trading on Wednesday.
- 3The ex vivo panel evaluation of xenograft models derived from 10 low-grade non-small cell lung cancer patients required a total of 10 mice.
So what's the key point?
Veraxa Biotech AG announced it will test drugs using a new method. Following this news, the stock price rose 3.7%.
Source Barrons.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.